| Title |
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, January 2014
|
| DOI | 10.2147/dmso.s38753 |
| Pubmed ID | |
| Authors |
Brian K Irons, Molly G Minze |
| Abstract |
Metformin is considered an initial drug of choice for type 2 diabetes mellitus by leading recommendations. When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of agents to treat hyperglycemia associated with type 2 diabetes mellitus. Each class of agent has its own benefit and safety profile. There are numerous factors to consider when selecting another agent in lieu of metformin including, but not limited to, overall efficacy in A1c reduction, adverse effect profile, cost, and patient preference. The number of factors influencing the decision process presents challenges and often no one specific agent is ideal. Each pharmacotherapeutic class of agents alternative to metformin for the treatment of hyperglycemia in type 2 diabetes mellitus as initial monotherapy is reviewed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| United Kingdom | 1 | <1% |
| Unknown | 132 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 19% |
| Student > Master | 19 | 14% |
| Researcher | 15 | 11% |
| Student > Postgraduate | 11 | 8% |
| Student > Ph. D. Student | 11 | 8% |
| Other | 25 | 19% |
| Unknown | 29 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 16% |
| Agricultural and Biological Sciences | 16 | 12% |
| Biochemistry, Genetics and Molecular Biology | 9 | 7% |
| Chemistry | 4 | 3% |
| Other | 11 | 8% |
| Unknown | 31 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2019.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#486
of 1,182 outputs
Outputs of similar age
#184,513
of 320,237 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#6
of 6 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,182 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,237 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.